Skip main navigation

Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases

Article
Please take some time to review this essay: Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases

ASO-based therapeutics, being able to modulate disease pathways are potential candidates for the currently incurable genetic neuromuscular diseases. However, current ASOs do not readily cross an intact blood-brain barrier and limit their application via intrathecal injections for central nervous system diseases. Successful ASO development for other neuromuscular diseases that primarily affect peripheral nerves and skeletal muscles will also require efficient delivery methods.

Please explore the biochemical modification of the oligonucleotide. If you are capable, please provide an alternative delivery system. Feel free to leave comments.

This article is from the free online

Pharmacotherapy: Understanding Biotechnology Products

Created by
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now